source
- Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune diseasePfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
- Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseasesPfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…